Journal article
Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection
Journal of virology, Vol.89(11), pp.6117-6120
06/2015
DOI: 10.1128/JVI.00446-15
PMCID: PMC4442417
PMID: 25787284
Abstract
Middle East respiratory syndrome (MERS) is a highly lethal pulmonary infection. Serum from convalescent MERS patients may provide some benefit but is not readily available. In contrast, nearly all camels in the Middle East have been infected with MERS-CoV. Here, we show that sera obtained from MERS-immune camels augment the kinetics of MERS-CoV clearance and reduce the severity of pathological changes in infected lungs, with efficacy proportional to the titer of MERS-CoV-neutralizing serum antibody. Middle East respiratory syndrome, caused by a coronavirus, is highly lethal, with a case fatality rate of 35 to 40%. No specific therapy is available, and care is generally supportive. One promising approach is passive administration of sera from convalescent human MERS patients or other animals to exposed or infected patients. The vast majority of, if not all, camels in the Middle East have been infected with MERS-CoV, and some contain high titers of antibody to the virus. Here, we show that this antibody is protective if delivered either prophylactically or therapeutically to mice infected with MERS-CoV, indicating that this may be a useful intervention in infected patients.
Details
- Title: Subtitle
- Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection
- Creators
- Jincun Zhao - Department of Microbiology, University of Iowa, Iowa City, Iowa, USA State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaRanawaka A P M Perera - The School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaGhazi Kayali - Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USADavid Meyerholz - Department of Pathology, University of Iowa, Iowa City, Iowa, USAStanley Perlman - Department of Microbiology, University of Iowa, Iowa City, Iowa, USA stanley-perlman@uiowa.edu malik@hku.hkMalik Peiris - The School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China stanley-perlman@uiowa.edu malik@hku.hk
- Resource Type
- Journal article
- Publication Details
- Journal of virology, Vol.89(11), pp.6117-6120
- DOI
- 10.1128/JVI.00446-15
- PMID
- 25787284
- PMCID
- PMC4442417
- NLM abbreviation
- J Virol
- ISSN
- 0022-538X
- eISSN
- 1098-5514
- Publisher
- United States
- Grant note
- HHSN272201400006C / PHS HHS R01 AI0901322 / NIAID NIH HHS P01 AI060699 / NIAID NIH HHS P30 DK054759 / NIDDK NIH HHS HHSN272201400006C / NIAID NIH HHS
- Language
- English
- Date published
- 06/2015
- Academic Unit
- Microbiology and Immunology; Stead Family Department of Pediatrics; Pathology; Iowa Neuroscience Institute; Infectious Disease (Pediatrics)
- Record Identifier
- 9983777355402771
Metrics
41 Record Views